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Electrical remodeling plays a pivotal role in maintaining the reentry during atrial ﬁbrillation. In this
study, we assessed inﬂuence of electrical remodeling on pharmacological manipulation of the atrial
refractoriness in rabbits. We used an atrial electrical remodeling model of the rabbit, subjected to rapid
atrial pacing (RAP; 600 beats/min) for 2e4 weeks, leading to shortening of atrial effective refractory
period (AERP). Intravenous administration of dl-sotalol (6 mg/kg), bepridil (1 mg/kg), amiodarone
(10 mg/kg) or vernakalant (3 mg/kg) signiﬁcantly prolonged the AERP both in the control and RAP
rabbits. The extents in the RAP rabbits were similar to those in the control animals. On the other hand,
prolonging effects of intravenously administered ranolazine (10 mg/kg) or tertiapin-Q (0.03 mg/kg) on
the AERP in the RAP rabbits were more potent than those in the control animals. These results suggest
that rapid pacing-induced electrical remodeling effectively modiﬁed the prolonging effects of ranolazine
and tertiapin-Q on the AERP in contrast to those of clinically available antiarrhythmic drugs, dl-sotalol,
bepridil amiodarone and vernakalant.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial ﬁbrillation (AF) is the most common sustained arrhythmia
found in clinical practice, which is closely related to an increased
long-term risk of stroke, heart failure, and all-cause mortality (1,2).
Class I or III antiarrhythmic drugs are primarily used for patients
with AF to suppress reentry in the atria via a prolonging action of
effective refractory period. However, the antiarrhythmic drugs
sometimes have limitations due to adverse effects such as a
decrease of ventricular conduction or contraction at therapeutic
dose ranges, leading to the modest efﬁcacy for AF (3e5).
The pathophysiology of AF has been a subject of active inves-
tigation for more than a century, and the mechanisms of AF are
recognized as being multifactorial and sharing properties of
reentry, automaticity, and triggered activity (3e5). Furthermore,
AF itself leads to various remodelings in the atria, such as the
shortening of the action potential duration and atrial effective
refractory period (AERP), an increase in heterogeneity of refrac-
toriness, changes in ion channel expression and conductivity, andara).
rmacological Society.
. Production and hosting by Elsedevelopment of ﬁbrosis (3e5). Inconveniently, such progressive
electro-anatomic remodelings of the atria facilitates perpetuation
of AF, which is often refractory to conventional drug therapy.
Sicilian Gambit classiﬁcation is a newer approach to select proper
antiarrhythmic drugs for an individual patient based on its mul-
tiple actions on arrhythmogenic mechanisms (6). Because of the
complex pathophysiology of AF, further pharmacological infor-
mation is needed to prescribe proper drugs for patients with
persistent AF.
To clarify inﬂuence of electrical remodeling on pharmacological
manipulation of the atrial refractoriness, in this study, we
compared effects of several antiarrhythmic drugs on the normal
and electrically remodeled atria in rabbits, since electrical remod-
eling plays a pivotal role in maintaining the reentry during AF
(3e5). We assessed following 6 drugs; dl-sotalol (a blocker of IKr
and ß-adrenoceptor), bepridil (a multi-ion channel blocker),
amiodarone (a blocker of multi-ion channels and adrenoceptor),
vernakalant (a multi-ion channel blocker), ranolazine (a late INa
blocker), and tertiapin-Q (an IK,ACh blocker). We used an atrial
electrical remodeling model of the rabbit, which was subjected to
rapid atrial pacing (600 beats/min) for 2e4 weeks, leading to
shortening of AERP. To avoid heart failure-related atrial remodeling,
experiments were performed using the heart with completevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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(180 beats/min).
2. Materials and methods
All animal experiments were reviewed and approved by the
Experimental Animal Committee of the R&D Department of TOA
EIYO Ltd, Fukushima Research Laboratories (Fukushima, Japan).
2.1. Rabbit model of rapid atrial pacing
Male New Zealand White rabbits (Japan SLC, Inc., Shizuoka,
Japan) weighing 3.0e3.5 kg were used for this study. The rabbits
were initially anesthetized with ketamine hydrochloride (35 mg/
kg, i.m.) and xylazine (5 mg/kg, i.m.), and the anesthesia was
maintained by a continuous intravenous infusion of ketamine hy-
drochloride (20 mg/kg/h) and xylazine (3 mg/kg/h). After intuba-
tion with a tracheal cannula, left thoracotomy was performed
under mechanical ventilation. Two pairs of recording/pacing elec-
trodes (Physiotech, Tokyo, Japan) were sutured to the left atrial
appendage (LAA) and left ventricle. The electrode leads were
tunneled subcutaneously to the back for recording cardiac electrical
activity and electrically pacing with an external pacemaker (PACE
101H, OSYPKA Medical, Berlin, Germany). The complete atrioven-
tricular block was induced using the catheter ablation technique, as
previously described (7), and the ventricle was electrically driven at
a pacing rate of 180 beats/min throughout the experiment. The
rabbits were divided into two groups as follows: control rabbits and
rabbits subjected to rapid atrial pacing (RAP). One week later, the
left atrium was electrically paced at 600 beats/min using an
external pacemaker (PACE 101H, OSYPKA Medical) with an outputFig. 1. Typical LAA electrograms and surface ECG in the control and rapid atrial pacing (RAP
RAP rabbits. (B) Representative electrograms of AF induced by burst pacing in control and
reactive atrial excitation. ECG; electrocardiogram, LAA; left atrial appendage.of twice-threshold voltage (n ¼ 24). On the other hand, the rapid
atrial pacing was not delivered in a group of control rabbits
(n ¼ 32).2.2. Hemodynamics and electrophysiological measurements
More than 2 weeks after the start of rapid atrial pacing, the
rabbit was anesthetized with ketamine hydrochloride (17 mg/kg,
i.m.) and xylazine (2.5 mg/kg, i.m.), and the anesthesia was
maintained by a continuous intravenous infusion of ketamine
hydrochloride (20 mg/kg/h) and xylazine (3 mg/kg/h). The surface
lead II electrocardiogram (ECG) was obtained from the limb elec-
trodes. An indwelling needle was placed in the central auricular
artery for monitoring of the blood pressure. After the rapid atrial
pacing was temporarily stopped, the blood pressure, surface ECG,
and atrial electrogram were monitored with a multi-channel
ampliﬁer (MEG-6108, Nihon Kohden, Tokyo, Japan). Each mea-
surement of ECG or atrial electrogram was the mean of 10
consecutive recordings.
The AERP was measured at basic cycle lengths of 250, 200 and
150 ms with a train of 8 basic stimuli (S1) followed by a premature
extrastimulus (S2) at 2-ms decrements using a programmable
stimulator (SEC-4103, Nihon Kohden, Tokyo, Japan) with twice-
threshold voltage at a 1-ms pulse duration. The AERP was deﬁned
as the shortest S1eS2 interval that captured the atria, as shown in
Fig. 1A. At each evaluation of the electrophysiological parameters,
the atrial diastolic threshold was measured by delivering 250 ms
cycle length pacing with a pulse width of 1 ms.
For induction of AF, the LAA was paced at 900 beats/min for 5 s
with 4 times of the diastolic threshold voltage using an electrical
stimulator (SEC-4103, Nihon Kohden, Tokyo, Japan). AF was deﬁned) rabbits. (A) Representative LAA electrograms for measurement of AERP in control and
RAP rabbits. A; atrial electrogram, V; ventricular electrogram. The arrows indicate the
Table 1
Cardiovascular and electrophysiological parameters.
Parameters Control RAP
Mean blood pressure (mmHg) 76 ± 1 77 ± 1
Atrial rate (bpm) 207 ± 7 190 ± 7
P-wave duration (ms) 38 ± 1 39 ± 1
QT interval (ms) 172 ± 2 175 ± 3
AERP CL ¼ 250 (ms) 76 ± 1 56 ± 1***
AERP CL ¼ 200 (ms) 77 ± 1 58 ± 1***
AERP CL ¼ 150 (ms) 77 ± 1 60 ± 1***
AF inducibility (%) 3 ± 2 57 ± 5***
AF duration (s) 0.1 ± 0.0 3.4 ± 0.9**
Data are represented as mean ± S.E.M. from the control rabbits (n ¼ 32) and rapid
atrial pacing (RAP) rabbits (n ¼ 24) more than 2 weeks after the start of rapid atrial
pacing. In the control rabbits, data of AF inducibility and its duration were obtained
from 23 out of 32 animals. **P < 0.01; ***P < 0.001, compared with control rabbits.
AERP, atrial effective refractory period; CL, cycle length; AF, atrial ﬁbrillation.
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irregular baseline of the ECG. The burst pacing was repeated 10
times, and the AF duration was calculated by averaging the sus-
tained period of AF after the burst pacing. When the atrial ﬁbril-
lation was sustained for >60 s, it was terminated electrically.
2.3. Experimental protocol
When analyzing effects of each drug on the atrium, the rapid
atrial pacing was stopped during the assessment. During the sta-
bilization period of 30 min, the AERP was measured to check an
extent of electrical remodeling of the atria. After baseline cardio-
vascular and electrophysiological variables were obtained, a drug
was administered intravenously via the marginal ear vein over
10 min, and each variable was assessed 10 min after the start of the
drug infusion. The dose of each drug except for ranolazine was
chosen based on our preliminary study using normal rabbits, where
the AERP was prolonged by 10e20 ms. Although ranolazine at
10 mg/kg did not prolonged the AERP up to the criterion in normal
rabbits, 10 mg/kg of ranolazine was chosen for this study, because
higher doses of ranolazine showed severe hypotension. After the
termination of the electrophysiological assessments, the rapid
atrial pacing was resumed.
The pharmacological evaluation with dl-sotalol, bepridil, amio-
darone, vernakalant, ranolazine or tertiapin-Q was performed 2e4
weeks after the start of RAP. Seven out of 24 rabbits receiving the
RAP were additionally used for pharmacological evaluation after a
washout period of more than 2 days. Since the elimination half-life
of amiodarone is known to be long (20e47 days) (8), no drug was
evaluated after the assessment of amiodarone.
2.4. Drugs
dl-Sotalol, bepridil hydrochloride and ranolazine dihydro-
chloride were purchased from Sigma Aldrich (St. Louis, MO, USA).
Amiodarone hydrochloride (Ancaron Inj™) was purchased from
Sanoﬁ Co., Ltd. (Tokyo, Japan). Vernakalant hydrochloride was
purchased from Haoyuan Chemexpress Co., Ltd. (Shanghai, China).
Tertiapin-Q was purchased from PEPTIDE institute Inc (Osaka,
Japan). Ketamine hydrochloride (Ketalar™) was purchased from
Daiichi-Sankyo (Tokyo, Japan). Xylazine (Selactar™) was purchased
from Bayer Health Care (Tokyo, Japan). dl-Sotalol, vernakalant and
tertiapin-Q were dissolved in saline. Amiodarone was diluted with
5% glucose. Bepridil was dissolved in saline containing 10% DMSO
and 5% Tween 80.
2.5. Statistical analysis
Data are presented as the mean ± S.E.M. The statistical sig-
niﬁcances of differences in paired data were evaluated by the
paired t-test, whereas those in unpaired data were evaluated by
Student's t test or Aspin-Welch t test. The statistical signiﬁcances
of multiple differences were evaluated by Tukey test. All data
analyses were performed using EXSUS version 7.7.1 (CAC EXICARE,
Osaka, Japan). P-value of <0.05 was considered as statistically
signiﬁcant.
3. Results
3.1. Electrophysiological characteristics of the RAP rabbits
The results of cardiovascular and electrophysiological variables
are summarized in Table 1. There was no signiﬁcant difference in
the mean blood pressure, atrial rate, P-wave duration or QT interval
between the two groups. The AERP in the RAP rabbits wassigniﬁcantly shorter than that in the control rabbits in each pacing
cycle length of 250, 200 or 150 ms. As shown in the Fig. 1B, AF was
effectively induced by burst pacing to the LAA in the RAP rabbits. AF
inducibility and duration in the RAP rabbits were signiﬁcantly
greater than those in the control rabbits.
3.2. Effects of 6 antiarrhythmic drugs on the AERP in the control
and RAP rabbits
After the cessation of rapid atrial pacing, we conﬁrmed that the
AERP was unchanged during the experimental period in the RAP
rabbits (n ¼ 6, data not shown). Figs. 2 and 3 summarize the effects
of intravenous administration of dl-sotalol (6 mg/kg, n ¼ 5 for each
group), bepridil (1 mg/kg, n ¼ 5 for each group), amiodarone
(10 mg/kg, n ¼ 5 for each group), vernakalant (3 mg/kg, n ¼ 5 for
each group), ranolazine (10 mg/kg, n ¼ 6 for each group) or
tertiapin-Q (0.03 mg/kg, n ¼ 5 for each group) on the AERP in the
control and RAP rabbits. dl-Sotalol, bepridil, amiodarone, and ver-
nakalant signiﬁcantly prolonged the AERPs at each pacing cycle
length in the control rabbits, and their extents were similar to those
in the RAP rabbits. Tertiapin-Q signiﬁcantly prolonged the AERP at
each pacing cycle length both in the control and RAP rabbits. On the
other hand, ranolazine signiﬁcantly prolonged the AERP only at a
pacing cycle length of 150 ms in the control rabbits, whereas the
drug signiﬁcantly prolonged the AERPs at all pacing cycle lengths in
the RAP rabbits. The extents of prolonging effect of ranolazine and
tertiapin-Q on the AERP in the RAP rabbits were greater than those
in the control animals.
3.3. Effects of 6 antiarrhythmic drugs on the burst pacing-induced
AF in the RAP rabbits
Effects of the 6 antiarrhythmic drugs on the AF inducibility and
AF duration are summarized in Table 2. There was no signiﬁcant
difference in baseline values among the drug treatment groups. The
drugs except for amiodarone signiﬁcantly reduced AF inducibility,
and amiodarone potentially decreased it (p ¼ 0.0817). The AF
duration was reduced after the administration of the antiar-
rhythmic drugs, which did not achieve conventional level of sta-
tistical signiﬁcance.
3.4. Effect of 6 antiarrhythmic drugs on the hemodynamics and ECG
parameters
The effects of 6 antiarrhythmic drugs on hemodynamics and
ECG parameters are summarized in Table 3. The mean blood
pressure was decreased by bepridil, amiodarone, vernakalant and
Fig. 2. Effects of dl-sotalol, bepridil and amiodarone on the atrial effective refractory period (AERP) in the control and rapid atrial pacing (RAP) rabbits. dl-Sotalol (left panels, 6 mg/
kg, n ¼ 5 for each group), bepridil (middle panels, 1 mg/kg, n ¼ 5 for each group) or amiodarone (right panels, 10 mg/kg, n ¼ 5 for each group) was intravenously administered to the
control or RAP rabbits. AERP was measured before and 10 min after the administration of each drug, which are shown in the lower panels. Upper panels show the extents of AERP-
prolonging effects. Each data represents the means ± S.E.M. **P < 0.01; ***P < 0.001, compared with corresponding baseline value (Baseline).
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rate was signiﬁcantly increased by tertiapin-Q in the control
rabbits as well as RAP rabbits. The P-wave duration was signiﬁ-
cantly prolonged by bepridil, amiodarone and vernakalant inVernakalant Rano
Fig. 3. Effects of vernakalant, ranolazine and tertiapin-Q on the atrial effective refractory per
3 mg/kg, n ¼ 5 for each group), ranolazine (middle panels; 10 mg/kg, n ¼ 6 for each grou
administered to the control or RAP rabbits. AERP was measured before and 10 min after the
the extents of AERP-prolonging effects. Each data represents the means ± S.E.M. *P < 0.0
yP < 0.05; yyP < 0.01; yyyP < 0.001, compared with corresponding control value (Control).control rabbits, whereas it was increased by vernakalant in the
RAP rabbits. The QT interval was prolonged by dl-sotalol, bepridil,
amiodarone, vernakalant and ranolazine both in the control and
RAP rabbits.lazine Tertiapin-Q
iod (AERP) in the control and rapid atrial pacing (RAP) rabbits. Vernakalant (left panels,
p) or tertiapin-Q (right panels; 0.03 mg/kg, n ¼ 5 for each group) was intravenously
administration of each drug, which are shown in the lower panels. Upper panels show
5; **P < 0.01; ***P < 0.001, compared with corresponding baseline value (Baseline).
Table 2
Effects of antiarrhythmic drugs on inducibility and duration of AF in rapid atrial
pacing rabbits.
AF inducibility (%) AF duration (s)
n Baseline Drug Baseline Drug
dl-Sotalol 5 60 ± 8 2 ± 2** 3.0 ± 1.8 0.0 ± 0.0
Bepridil 5 64 ± 8 24 ± 9** 3.1 ± 1.3 1.0 ± 0.6
Amiodarone 5 36 ± 16 2 ± 2 1.7 ± 0.8 0.0 ± 0.0
Vernakalant 5 60 ± 16 4 ± 4* 6.3 ± 3.2 0.1 ± 0.1
Ranolazine 6 47 ± 10 7 ± 3** 5.5 ± 2.3 0.2 ± 0.1
Tertiapin-Q 5 68 ± 4 28 ± 13* 4.0 ± 1.4 2.2 ± 2.0
Data are represented as mean ± S.E.M. *P < 0.05; **P < 0.01, compared with cor-
responding baseline value.
T. Chiba et al. / Journal of Pharmacological Sciences 130 (2016) 170e1761744. Discussion
In this study, we compared electrophysiological effects of 6
antiarrhythmic drugs on the normal and electrically remodeled
atria in rabbits. The extents of prolonging effects of dl-sotalol,
bepridil, amiodarone or vernakalant on the AERP in the RAP rabbits
were similar to those in the control animals. On the other hand, the
AERP-prolonging effects of ranolazine or tertiapin-Q in the RAP
rabbits were more potent than those in the control animals.4.1. Characteristics of rapid atrial pacing model in rabbits
Longer durations of AF or RAP have been shown to induce
shortening of the AERP, which is related to the lower success rates
of various antiﬁbrillatory treatments when the arrhythmia has
lasted for a longer period (3e5). As summarized in Table 1, the AERP
was shorter in rabbits receiving RAP for 2e4 weeks than in control
animals, which may be associated with greater inducibility and
duration of AF in this animal model. Since the P-wave durationwas
not different between the two animal groups, neither atrial
enlargement nor disturbance of intra-atrial conduction associated
with congestive heart failure might be induced in the RAP rabbits,
whose ventricular rate was maintained at 180 beats/min after the
creation of complete atrioventricular block. The mechanisms of
AERP shortening after RAP have been proposed using animal
models, in which a pronounced reduction of the action potential
duration in the atria are associated with reduced ICa,L and Ito causedTable 3
Effects of antiarrhythmic drugs on hemodynamics and electrocardiogram (ECG) parame
MBP (mmHg) Atrial rate (bpm)
Baseline Drug Baseline Dru
dl-Sotalol
Control (n ¼ 5) 72 ± 4 75 ± 4 214 ± 20 188
RAP (n ¼ 5) 78 ± 2 78 ± 1 217 ± 12 197
Bepridil
Control (n ¼ 5) 75 ± 4 57 ± 4*** 196 ± 19 209
RAP (n ¼ 5) 75 ± 4 56 ± 3*** 170 ± 15 188
Amiodarone
Control (n ¼ 5) 87 ± 5 44 ± 2*** 184 ± 22 205
RAP (n ¼ 5) 80 ± 3 40 ± 2*** 175 ± 12 179
Vernakalant
Control (n ¼ 5) 74 ± 1 64 ± 2* 228 ± 5 228
RAP (n ¼ 5) 79 ± 2 70 ± 1* 181 ± 15 189
Ranolazine
Control (n ¼ 6) 76 ± 4 53 ± 7*** 199 ± 19 233
RAP (n ¼ 6) 73 ± 4 51 ± 2*** 194 ± 17 217
Tertiapin-Q
Control (n ¼ 5) 83 ± 2 82 ± 2 204 ± 8 233
RAP (n ¼ 5) 75 ± 3 74 ± 3 184 ± 11 220
Data are represented as mean ± S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001, compared wiby the downregulation of the underlying Cav1.2 and Kv4.3 subunit
expression as well as an increase in constitutively active IK,ACh,
whereas IK1, rapid delayed-rectiﬁer Kþ current, IKs, IKur or ICa,T was
unaltered (3e5,9e11). We speculate that such mechanisms may be
essentially involved in the electrically remodeled atria in the cur-
rent RAP rabbits, which should be conﬁrmed biologically as well as
electrophysiologically in the future.4.2. Comparison of AERP-prolonging effect of 6 antiarrhythmic
drugs in the normal and electrically remodeled atrium
Based on the Guidelines for Pharmacotherapy of AF by the
Japanese Circulation Society (1), potent Naþ channel blockers
including pilsicainide and cibenzoline are recommended as phar-
macological cardioversion for patients with paroxysmal AF lasting
<48 h with no clinically signiﬁcant structural disease, whereas only
bepridil can be considered for patients with AF lasting >7 days with
normal cardiac function and QT interval. This may imply that
antiarrhythmic drugs being clinically effective in the acute phase of
AF are not always available for the treatment of patients with
persistent AF associated with pathophysiological remodeling of the
atrium. In the present study, bepridil prolonged the AERP both in
the control and RAP rabbits, whose extents were almost the same
between the experimental groups, as shown in Fig. 2. Similar re-
sults were obtained by dl-sotalol, amiodarone and vernakalant in
this study. On the other hand, ranolazine and tertiapin-Q prolonged
the AERP in both experimental groups; however, the extent in the
RAP rabbits was signiﬁcantly greater than that in the control rab-
bits. These results suggest that rapid pacing-induced electrical
remodeling effectively modiﬁed the prolonging effects of ranola-
zine and tertiapin-Q on the AERP in contrast to those of clinically
available antiarrhythmic drugs, dl-sotalol, bepridil amiodarone and
vernakalant. As shown in the Table 2, the 6 drugs essentially have
anti-AF effects in the RAP rabbits. However, obvious relationship
was not observed between prolongations of AERP and anti-AF ef-
fects. Since AF has been demonstrated to be caused by abnormal
focal excitability as well as random reentry of multiple wavelets in
animals and humans (1,3e5), Naþ channel-blocking properties of
some drugs including amiodarone might counteract the burst
pacing-induced AF associated with components of abnormal focal
excitability.ters in the control and rapid atrial pacing (RAP) rabbits.
P-wave duration (ms) QT interval (ms)
g Baseline Drug Baseline Drug
± 4 39 ± 2 38 ± 2 170 ± 5 223 ± 5***
± 5 41 ± 3 41 ± 2 170 ± 4 220 ± 7***
± 19 38 ± 1 40 ± 1* 174 ± 7 182 ± 5*
± 9 41 ± 2 43 ± 2 164 ± 5 171 ± 7*
± 6 39 ± 2 43 ± 2* 174 ± 7 184 ± 8*
± 8 42 ± 1 42 ± 1 171 ± 5 182 ± 6*
± 5 38 ± 1 40 ± 0* 181 ± 6 199 ± 8**
± 18 42 ± 2 44 ± 3* 171 ± 5 189 ± 7**
± 6 34 ± 2 36 ± 2 169 ± 8 181 ± 6**
± 9 37 ± 2 39 ± 2 164 ± 6 180 ± 4**
± 3** 37 ± 2 37 ± 2 170 ± 4 171 ± 4
± 9** 41 ± 2 39 ± 1 170 ± 8 171 ± 8
th corresponding baseline value.
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revealed that an antianginal drug ranolazine suppresses the late
INa and IKr with IC50 values of 5.9 and 11.5 mM, respectively, which
are more potent than its effects on the peak INa and ICa,L (IC50; 294
and 296 mM, respectively) (12,13). Since ranolazine prolonged the
QT interval, as shown in Table 3, it is estimated that the current
dose of the drug (10 mg/kg) effectively inhibited the IKr as well as
late INa. The P-wave duration, roughly reﬂecting intra-atrial con-
duction time, was hardly affected by ranolazine, which can be
explained by its weaker effects on the peak INa than the late INa
and IKr. Pharmacological inhibition of late INa generally abbrevi-
ates the action potential duration (14,15), which can theoretically
counteract the component of IKr-inhibiting effect of ranolazine on
the AERP. On the other hand, contribution of late INa is known to
be greater in the longer action potential duration (14,15). Since the
AERP was signiﬁcantly abbreviated in the electrically remodeled
atria, the integral of the late INa was estimated to be smaller in the
RAP model, which may partly explain why ranolazine prolonged
the AERP in the RAP rabbits more greatly than in the control
animals.
Tertiapin-Q is an IK,ACh blocker derived from bee venom, known
as a useful peptide for investigating a therapeutic utility of IK,ACh
blockade (16). In this study, tertiapin-Q prolonged the AERP in both
experimental groups, and the extent in the RAP rabbits was
signiﬁcantly greater than that in the control rabbits. A previous
electrophysiological study has demonstrated that IK,ACh is consti-
tutively active in the isolated atrial cardiomyocytes from patients
with long-term AF compared with non-AF patients (17), which was
also supported by an experimental study using dogs with RAP (18).
Thus, similar mechanisms might be involved in the atria of our RAP
rabbit model. On the other hand, bepridil (19), amiodarone (20) and
vernakalant (21) have been reported to suppress IK,ACh with IC50
values of 2e10 mM, whose potencies were relatively similar to IKr-
blocking effect of each drug. The reason is still unclear why AERP-
prolonging properties of bepridil, amiodarone and vernakalant
were different from that of tertiapin-Q. Since information is limited
regarding afﬁnities of the drugs used in this study for channels of
IK,ACh and constitutively-active IK,ACh (9), this should be further
investigated for discovering new type of anti-AF drugs.4.3. Comparison of hemodynamic and electrophysiological effects
of 6 antiarrhythmic drugs in the normal and electrically remodeled
rabbits
In this study, bepridil, amiodarone, vernakalant and ranolazine
decreased the mean blood pressure in both rabbit models, whereas
dl-sotalol or tertiapin-Q hardly affected it, which are essentially in
accordance with previous in vivo studies using dogs or rabbits
(22e27). The atrial rate was signiﬁcantly increased by tertiapin-Q
in the control rabbits as well as RAP rabbits, which might be
associated with counteraction of intrinsic parasympathetic nerve
activity through its IK,ACh-blocking property (28). Bepridil and
amiodarone prolonged the P-wave duration in the control rabbits.
Since it was not observed in the RAP rabbits, Naþ channel-blocking
actions of these drugs in the atria might be altered by electrical
remodelings. In contrast, vernakalant prolonged the P-wave in both
animal groups in this study, which was essentially in accordance
with previous studies (29,30). dl-Sotalol, bepridil, amiodarone,
vernakalant and ranolazine prolonged the QT interval at the AERP-
prolonging dose, which were in accordance with previous studies
(23e26,31). Since antiarrhythmic drugs often exert some cardio-
vascular side effects at effective doses, discovery of drugs with
more potent AERP-prolonging action in the remodeled atrium than
normal atrium are expected for greater safety margin.4.4. Study limitations
This study may partly provide information for the mechanisms
of electrical remodeling in the RAP rabbit heart as well as impact on
the drug development efforts aimed at improving existing antiar-
rhythmic drugs. The mechanisms of electrical and ionic remodeling
during atrial tachycardia; namely, reduction of ICa,L and Ito and
increment of constitutive IK,ACh, have been demonstrated to be
essentially similar between human AF and animal AF model
(3e5,9e11). However, an earlier in vitro electrophysiological study
has demonstrated that the AERP in rabbits is much shorter than
that in human (87 ms vs 324 ms) and that sensitivity of drugs such
as ﬂecainide and quinidine to the AERP in rabbit is lower than that
in human (32). Thus, caution should be taken in extrapolating our
ﬁndings to AERP-prolonging effects in AF patients.
4.5. Conclusions
Rapid pacing-induced electrical remodeling effectivelymodiﬁed
the prolonging effects of ranolazine and tertiapin-Q on the AERP in
contrast to those of clinically available antiarrhythmic drugs, dl-
sotalol, bepridil amiodarone and vernakalant. This understanding
will be useful for prescribers to select antiarrhythmic drugs for AF
patients with electrically remodeled atria.
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